Multiple myeloma patients experience high response rate with new 3-drug combination

A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

Read the whole article on Physorg

More from Physorg